Trials / Completed
CompletedNCT03656705
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
Clinical Investigation of Chimeric Costimulatory Converting Receptor(CCCR)-Modified NK92 Cells in Previously Treated Advanced Non-small Cell Lung Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Henan Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical investigation is to evaluate the safety and effects of CCCR-modified NK92(CCCR-NK92)infusions in previously treated advanced non-small cell lung carcinoma(NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CCCR-NK92 cells | CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment. |
Timeline
- Start date
- 2018-09-29
- Primary completion
- 2020-11-30
- Completion
- 2020-12-31
- First posted
- 2018-09-04
- Last updated
- 2023-07-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03656705. Inclusion in this directory is not an endorsement.